1.Periodontics is the foundation for any other dental field.
Chinese Journal of Stomatology 2011;46(9):516-518
2.Recommendations for dental clinical management in China.
West China Journal of Stomatology 2010;28(6):577-579
Comparing of dental clinical management in the USA, the authors would like to make some suggestions to Chinese colleagues in the following five aspects. They are included disadvantages of using disposable examination kit, using chair side X-ray machine, stopping using chair side spittoon, using topical anesthesia instead of using topical disinfection, patient management in the university hospital setting. The aims of this article were to open discussion and improve Chinese dental clinical management.
China
;
Dental Clinics
;
organization & administration
;
Humans
3.The applications of periodontal gingival surgery. Ⅱ: alternative materials.
West China Journal of Stomatology 2018;36(2):117-122
The main purposes of periodontal graft surgery include achieving root coverage, improving the clinical attachment level and keratinized tissue, and advancing the procedure of periodontal plastic surgery. Autogenous graft, such as subepithelial connective tissue graft-based procedure, provide the best outcomes for mean and complete root coverage, as well as increase in keratinized tissue. However, a disadvantage of the procedure is in the location of the operation itself: the additional surgical site (palate). Therefore, clinicians are always looking for graft substitutes. This article will discuss the evidence supporting the use of 1) acellular dermal matrix (ADM); 2) xenogeneic collagen matrix (XCM); 3) recombinant human platelet-derived growth factor (rhPDGF); 4) enamel matrix derivative (EMD); 5) guided tissue regeneration (GTR); 6) living cellular construct (LCC), all of which are used in conjunction with coronally advanced flaps as alternatives to autogenous donor tissue. The decision tree for treatments of Miller recession-type defects are also discussed.
4.Effects of Chinese herb compound Naoyikang on expression of choline acetyltransferase in brain of rats with Alzheimer's disease.
Jin-Song GENG ; Ai-Ling ZHOU ; Hai-Yan SHI ; Ya-Er HU ; Jia-Hui MAO ; Yan ZHU
China Journal of Chinese Materia Medica 2008;33(9):1071-1074
OBJECTIVETo observe the effects of Naoyikang (NYK) on expression of choline acetyltransferase (ChAT) in brain of rats with Alzheimer' s disease (AD).
METHODBilateral infusions of Ibotenic acid (IBO) into nucleus basalis of Meynert (NBM) using hamilton syringe and stereotaxic apparatus were adopted to establish the rat model of AD. After intragastrically administrated with different solution for 28 days, immunohistochemistry and Western-blot were adopted to study the expression of ChAT in frontal cortex of AD rats.
RESULTNYK could improve the morphology and increase the number of ChAT immunoreactive neurons, and significantly promote ChAT protein expression.
CONCLUSIONNYK may be able to increase the synthesis of acetylcholine (ACh) through elevating the expression of ChAT protein, thus improving the level of brain ACh so as to protect central cholinergic neurons.
Alzheimer Disease ; enzymology ; Animals ; Blotting, Western ; Brain ; drug effects ; enzymology ; Choline O-Acetyltransferase ; metabolism ; Disease Models, Animal ; Drugs, Chinese Herbal ; pharmacology ; Gene Expression Regulation ; drug effects ; Immunohistochemistry ; Male ; Rats ; Rats, Sprague-Dawley
5.DNA Immunization of Hepatitis E Virus (HEV)
Dong-mei, LU ; Er-jia, CHEN ; Tian-hong, XIE ; Jun-ying ZHUANG ; Yong, LIU ; Chun-hong, LI ; Mao-sheng, SUN ; Chang-bai, DAI
Virologica Sinica 2001;16(2):131-134
Two plasmid constructs, pcE2 and pcE3, containing 3' fragment of open reading frame 2 (ORF2,1163 bp) of hepatitis E virus (HEV) and full-length ORF3 (369 bp), were injected into bilateral tibialis of Swiss mice respectively,for three times (0, 2nd and 4th weeks) and observed the HEV IgG by ELISA. HEV IgG was induced after the injection of pcE2 or pcE3 or both, and the percentage of seraconversion was 100% after two weeks of the third injection. Compared with injection of either construct, the antibody titers were higher in the group with combined injection of two constructs.
6.Impact of KIT D816 mutation on salvage therapy in relapsed acute myeloid leukemia with t(8;21) translocation.
Ben Fa GONG ; Ye Hui TAN ; Ai Jun LIAO ; Jian LI ; Yue Ying MAO ; Ning LU ; Yi DING ; Er Lie JIANG ; Tie Jun GONG ; Zhi Lin JIA ; Yu SUN ; Bing Zong LI ; Shu Chuan LIU ; Juan DU ; Wen Rong HUANG ; Hui WEI ; Jian Xiang WANG
Chinese Journal of Hematology 2018;39(6):460-464
Objective: To evaluate the impact of KIT D816 mutation on the salvage therapy in relapsed acute myeloid leukemia (AML) with t(8;21) translocation. Method: The characteristics of the first relapsed AML with t(8;21) translocation from 10 hospitals were retrospectively collected, complete remission (CR(2)) rate after one course salvage chemotherapy and the relationship between KIT mutation and CR(2) rate was analyzed. Results: 68 cases were enrolled in this study, and 30 cases (44.1%) achieved CR(2). All patients received KIT mutation detection, and KIT D816 mutation was identified in 26 cases. The KIT D816 positive group had significantly lower CR(2) compared with non-KIT D816 group (23.1% vs 57.1%, χ(2)=7.559, P=0.006), and patients with longer CR(1) duration achieved significantly higher CR(2) than those with CR(1) duration less than 12 months (74.1% vs 31.9%, χ(2)=9.192, P=0.002). KIT D816 mutation was tightly related to shorter CR(1) duration. No significant difference of 2 years post relapse survival was observed between KIT D816 mutation and non-KIT D816 mutation group. Conclusion: KIT D816 mutation at diagnosis was an adverse factor on the salvage therapy in relapsed AML with t(8;21) translocation, significantly related to shorter CR1 duration, and can be used for prediction of salvage therapy response. KIT D816 mutation could guide the decision-making of salvage therapy in relapsed AML with t(8;21) translocation.
Antineoplastic Combined Chemotherapy Protocols
;
Cytarabine
;
Humans
;
Leukemia, Myeloid, Acute/therapy*
;
Prognosis
;
Retrospective Studies
;
Salvage Therapy